THERAPEUTICS
Dexamethasone and placebo did not differ for respiratory status change or hospital admission in infants with acute bronchiolitis
| The first 150 words of the full text of this article appear below. |
H M Corneli
Dr H M Corneli, University of Utah, Salt Lake City, UT, USA; corneli@med.utah.edu
STUDY DESIGN
randomised placebo controlled trial (RCT).
concealed.
blinded (study and emergency department [ED] staff, and guardians of infants).
STUDY QUESTION
20 EDs in the USA.
600 infants, 2–12 months of age (mean age 5.1 mo, 62% boys for 598 infants), who presented to the ED with a first episode of bronchiolitis (wheezing with no prior wheezing, asthma, or bronchodilator use before current illness) that was moderate to severe (
6 on the Respiratory Distress Assessment Instrument [RDAI]) and attended
7 days after symptom onset. Exclusion criteria included past adverse reaction to dexamethasone, corticosteroid use within 14 days, premature birth, critical illness, known heart or lung disease, immunosuppression or immunodeficiency, and active or recent exposure to varicella.
305 infants were assigned to a single dose of oral dexamethasone (1 mg/kg, maximum 12 mg) and 295 were assigned to
University of Alberta, Edmonton, Alberta, Canada
University of Ottawa, Ottawa, Ontario, Canada
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
